|
Market Closed -
London S.E.
12:35:04 2026-10-28 EDT
|
5-day change | 1st Jan Change | ||
| 2,050.00 GBX | +3.02% |
|
+5.13% | +7.61% |
| 10-26 | EARNINGS AND TRADING: Quadrise starts strategic review as losses mount | AN |
| 10-26 | Bioventix PLC Reports Earnings Results for the Full Year Ended June 30, 2026 | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 138M | |||||
| 63.48B | |||||
| 54.55B | |||||
| 53.59B | |||||
| 44.75B | |||||
| 41.62B |
- Stock Market
- Stocks
- BVXP Stock
- Charts Bioventix PLC
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
